LAS VEGAS, Oct. 5, 2009 (GLOBE NEWSWIRE) -- Cardio Infrared Technologies, Inc. (Pink Sheets:CDOI) (www.cardio-cor.com), a leading Health and Wellness technology and marketing company, announced today that the clinical trials being conducted in Pennsylvania completed Phase I earlier this year and demonstrated the efficacy portion of the trials. Phase II, which has been underway for 6 months, has been testing the effects on Detoxification and will be available by the end of this year.
Wayne Bailey, President and CEO of Cardio Infrared Technologies, Inc., stated: "The second phase of the clinical trials are within two months of completion. The expanded number of people involved in the second phase is providing a tremendous amount of additional information and data on the Cardio-Cor system. The results from the expanded Phase II are reported to be superior to those released in the first phase and additional levels of study are showing amazing results according to the community of patients involved. The expanded basis of the second phase of the study is concerned not only with weight and inch loss but also on detoxification and the tested results of infrared on the body. The report on the second phase is scheduled to be completed before the Las Vegas Anti-Aging show in December. The third phase of the Clinicals will be a comparison of the Cardio-Cor ExerBike vs. a treadmill which will document the additional benefits of using the Cardio-Cor over any other type of exercise equipment available to the public."
The clinical trials that were completed in Italy will also be released within the next three months. The Clinicals from Italy were completed using Italian guidelines, not FDA standards. They show vast weight, inch and cellulite loss. They also address detoxification and many of the other issues that our Phase II study is now addressing. The release of the additional studies will add validity to the technology and products of Cardio Infrared Technologies.
About Cardio Infrared Technologies, Inc.
Cardio Infrared Technologies, Inc. is a technology and marketing company, which is focused on developing the revolutionary and evolutionary process of combining exercise equipment with medical benefits that go far beyond the normal benefits of standard exercise equipment. Cardio Infrared Technologies, Inc. is committed to continue marketing this equipment to the exercise and medical markets and to aggressively expand the market to every country around the world. The equipment has already been featured on Good Morning America and The View. Cardio Infrared Technologies, Inc. also has an aggressive growth plan that includes acquisitions and development of innovative new equipment and programs in the exercise and medical industries.
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.The words or phrases "would be," "would allow," "intends to'" "will likely result," "are expected to," "will continue," "anticipate," "expect," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "considers," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. These include the company's historic lack of profitability, end user customer acceptance and actual demand, which may differ significantly from expectations, the need for the company to manage its growth, the need to raise funds for operations and other risks within the regulation of the industry. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company's past performance is not necessarily indicative of its future performance. The Company does not undertake, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, events or circumstances after the date of such statement.